Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nurses take on the hidden symptom burden of kidney disease

NCT ID NCT07815639

Symptom relief Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

People with advanced kidney disease often face fatigue, itching, pain, and sleep problems that disrupt daily life and strain caregivers. Researchers are testing a nurse-led program called COMFORT that helps patients and their informal caregivers recognize and manage these symptoms. The study enrolls 56 adults with advanced kidney disease, assigning some to usual care and others to usual care plus the program over about three months. The goal is to see whether the program can be delivered as planned and whether patients, caregivers, and nurses find it acceptable, not to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a tailored, nurse-led symptom management program called COMFORT
What this could lead to
If it works, this could give kidney care teams a practical way to help patients and caregivers track and manage symptoms together. It could also set the stage for a larger trial to test whether the program improves quality of life.
What could go wrong
This is a small feasibility study, so it cannot show whether the program actually reduces symptoms. The results may not apply to other kidney care settings, and the program may prove hard to deliver as planned.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients: * Age 18 years or older * Advanced kidney disease * At least one symptom with a score ≥2 on the Integrated Palliative care Outcome Scale-Renal (IPOS-Renal) * Receiving haemodialysis, peritoneal dialysis, conservative kidney management, or predialysis care * Able to provide informed consent Informal caregivers: * Age 18 years or older * Identified by a participating patient as an informal caregiver or close relative * Able to provide informed consent Exclusion Criteria: Patients: * Unable to speak or read Danish * Unable to provide informed consent * Unable to complete study questionnaires * Severe psychiatric disorder Informal caregivers: * Unable to speak Danish * Unable to complete study questionnaires * Unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (stages 4 and 5) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (stages 4 and 5)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, Central Jutland, 8200, Denmark

  • Rigshospitalet, Copenhagen University Hospital

    Copenhagen, Capital Region, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.